{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:03:43Z","timestamp":1770743023415,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ygyno.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T19:37:36Z","timestamp":1716838656000},"page":"212-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial"],"prefix":"10.1016","volume":"187","author":[{"given":"Guangwen","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haolin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 6","key":"10.1016\/j.ygyno.2024.05.005_bb0005","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2024.05.005_bb0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des cancers Ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0020","doi-asserted-by":"crossref","first-page":"viii13","DOI":"10.1093\/annonc\/mdx446","article-title":"Acquired chemotherapy resistance in ovarian cancer","volume":"28","author":"Christie","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0025","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0030","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4880355","article-title":"Antiangiogenic strategies in epithelial ovarian cancer: mechanism, resistance, and combination therapy","volume":"2022","author":"Jin","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0035","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/gb-2005-6-2-209","article-title":"The vascular endothelial growth factor (VEGF) family: Angiogenic factors in health and disease","volume":"6","author":"Holmes","year":"2005","journal-title":"Genome Biol."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0045","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/biom11010128","article-title":"Exploring the intracrine functions of VEGF-A","volume":"11","author":"Wiszniak","year":"2021","journal-title":"Biomolecules"},{"issue":"Suppl","key":"10.1016\/j.ygyno.2024.05.005_bb0050","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-angiogenic agents in ovarian cancer: past, present, and future","volume":"27","author":"Monk","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0055","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/15384047.2017.1282019","article-title":"Molecular targeting of VEGF\/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo","volume":"18","author":"Liu","year":"2017","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0060","first-page":"E5226","article-title":"Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ygyno.2024.05.005_bb0065","series-title":"Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7\u201310. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P001","article-title":"The anti-angiogenic antibody BD0801 demonstrates better anti-tumor activity than bevacizumab and synergize with chemotherapies in multiple tumor models [abstract]","author":"Xue","year":"2021"},{"key":"10.1016\/j.ygyno.2024.05.005_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101540","article-title":"Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia\/Ib open label, dose-escalation trials","volume":"8","author":"Mao","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0075","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.16601","article-title":"Bevacizumab and gastrointestinal perforations: a review from the FDA adverse event reporting system (FAERS) database","volume":"54","author":"Wichelmann","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0080","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2174\/1389450117666160502150237","article-title":"The benefits and side effects of bevacizumab for the treatment of recurrent ovarian cancer","volume":"18","author":"Zhang","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ygyno.2024.05.005_bb0085","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0090","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0095","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.2013.54.7299","article-title":"Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer","volume":"32","author":"Liu","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0100","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00280-022-04418-2","article-title":"Anti-drug antibodies in the current management of cancer","volume":"89","author":"Borreg\u00f3n","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.biologicals.2011.01.006","article-title":"Taking immunogenicity assessment of therapeutic proteins to the next level","volume":"39","author":"B\u00fcttel","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.ygyno.2024.05.005_bb0110","first-page":"335","article-title":"Immunologic responses to therapeutic biologic agents","volume":"18","author":"Purcell","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.ygyno.2024.05.005_bb0115","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.tibtech.2010.07.001","article-title":"Pharmacokinetic, pharmacodynamics, and immunogenicity comparability assessment strategies for monoclonal antibodies","volume":"28","author":"Putnam","year":"2010","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ygyno.2024.05.005_bb0120","doi-asserted-by":"crossref","first-page":"682","DOI":"10.4161\/mabs.2.6.13601","article-title":"Have we overestimated the benefit of human(ized) antibodies?","volume":"2","author":"Getts","year":"2010","journal-title":"mAbs"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824002178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824002178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:42:26Z","timestamp":1762231346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824002178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":24,"alternative-id":["S0090825824002178"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}